Literature DB >> 7293215

Biliary excretion, metabolism and enterohepatic circulation of buprenorphine.

D Brewster, M J Humphrey, M A McLeavy.   

Abstract

1. After intramuscular administration of [3H]buprenorphine to rats, dogs, rhesus monkeys and one human volunteer, most of the dosed radioactivity was excreted in the faeces, indicating biliary excretion and a possible enterohepatic circulation of the drug in these species. 2. After intravenous administration of [3H]buprenorphine (100 microgram/kg) to bile-duct cannulated rats, over 90% of the administered radioactivity was excreted in bile within 48 h after dosing. 3. The major drug-related component in rat bile was buprenorphine glucuronide. N-Dealkylated buprenorphine (again conjugated) was also present and a sex difference in the extent of N-dealkylation was apparent. 4. Intraduodenal infusion of rats with bile from rats dosed with [3H]buprenorphine produced a slow, although extensive, excretion of drug-related material in the bile of the recipient animals.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7293215     DOI: 10.3109/00498258109045291

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  14 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes.

Authors:  Yan Chang; David E Moody
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

4.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

Review 6.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

7.  Voriconazole greatly increases the exposure to oral buprenorphine.

Authors:  Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

8.  Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

Authors:  Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Kristiina Kuusniemi; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari
Journal:  Eur J Clin Pharmacol       Date:  2016-08-10       Impact factor: 2.953

9.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

Review 10.  Management of chronic pain in the elderly: focus on transdermal buprenorphine.

Authors:  Nalini Vadivelu; Roberta L Hines
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.